AFDN and acute myeloid leukemia: Five specific fusions account for 86.0% (KMT2A-MLLT4 28.1%, KMT2A-MLLT3 24.6%, KMT2A-MLLT10 19.3%, KMT2A-MLLT1 7.0%, and KMT2A-ELL 7.0%) of all KMT2A fusions in AML.